Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229216 | 1.00 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12506322 | 0.84 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13142865 | 0.83 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL473922 | 0.82 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18827257 | 0.82 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24850734 | 0.81 | KDM4E (0.42) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16577186 | 0.80 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9962914 | 0.78 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13295204 | 0.78 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL23143030 | 0.78 | MAPT (0.39) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208014-B2 | Compositions and methods for the treatment of neurological disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2019-02-19 | — | — | US | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9738631-B2 | Compositions and methods for the treatment of neurological disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9642915-B2 | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9522884-B2 | Compositions and methods for the treatment of metabolic disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-12-20 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9499526-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126567-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119453-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150111932-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150087674-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087697-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087670-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | LTA4H, LTC4S, ALOX5 | KDM4E 4020/4885MAPT 2832/4885THRB 2446/4885 |
| US-20150087674-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN | OPRK1, OPRM1, OPRD1 | KDM4E 3697/4885MAPT 122/4885THRB 1729/4885 |
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | F2, F12, F5 | KDM4E 4600/4885MAPT 2680/4885THRB 985/4885 |
| US-20150126567-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY | TTR, TNNC1, APP | KDM4E 4853/4885MAPT 26/4885THRB 1738/4885 |
| US-20150119453-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | BRCA1, APC, MSH2 | KDM4E 4398/4885MAPT 123/4885THRB 1688/4885 |
| US-20150087670-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HLA-DRB1, TRPV1, NDUFB11 | KDM4E 4843/4885MAPT 215/4885THRB 2573/4885 |
| US-20150111932-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS | LPXN, HNRNPU, KYNU | KDM4E 4587/4885MAPT 221/4885THRB 2245/4885 |
| US-10208014-B2 | Compositions and methods for the treatment of neurological disorders | APC, PSEN1, APP | KDM4E 3858/4885MAPT 10/4885THRB 2856/4885 |
| US-20150087697-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN | TNNC1, MUSK, OPRK1 | KDM4E 4737/4885MAPT 991/4885THRB 2285/4885 |
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | PARK7, HTT, SNCA | KDM4E 4838/4885MAPT 11/4885THRB 4112/4885 |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | IL1B, IAPP, CXCL12 | KDM4E 4376/4885MAPT 852/4885THRB 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.